We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Philips (PHG) Expands Portfolio With BioTelemetry Acquisition
Read MoreHide Full Article
Koninklijke Philips N.V. (PHG - Free Report) recently inked an agreement to acquire BioTelemetry (BEAT - Free Report) , a provider of remote cardiac diagnostics and monitoring in the United States.
Per the deal, Philips will make a cash tender offer to buy all of BioTelemetry’s issued and outstanding shares for $72 per share. The implied enterprise value, including BioTelemetry’s cash and debt, is $2.8 billion.
Additionally, Philips will incorporate roughly 1,900 BioTelemetry employees in its Connected Care business segment. Further, the company expects to complete the acquisition in the first quarter of 2021.
Rationale Behind the Acquisition
The integration of BioTelemetry’s cardiac diagnostics and monitoring solutions with Philips’ existing portfolio, which includes real-time patient monitoring, therapeutic devices, telehealth and informatics, drives the expansion of the latter’s cardiac care portfolio.
Koninklijke Philips N.V. Price, Consensus and EPS Surprise
The acquisition enhances the company’s patient care management capabilities by improving patient care across care settings for multiple diseases and medical conditions at both hospitals and homes.
Philips provides services to approximately 300 million patients in hospitals and 10 million sleep and respiratory care patients per year in their homes. BioTelemetry monitors more than 1 million patients per year and above 30,000 unique referring physicians per month. Notably, the integration expands Philips’ customer base and will drive top-line growth in the long haul.
Further, the company expects the buyout to aid revenue growth and adjusted EBITA margin expansion in 2021. Moreover, the EBITA margin is expected to surpass 20% by 2025.
The growth will be majorly driven by cross-selling opportunities, geographical expansion, along with innovation in the company’s product line-up, such as Philips’ Health Suite digital platform.
Notably, Philips’ Connected Care segment benefits from the coronavirus-induced elevated demand in both Sleep & Respiratory Care and Monitoring & Analytics businesses.
Further, strong demand for patient monitors, hospital ventilators, computed tomography and portable ultrasound systems led by the pandemic is a key catalyst. Moreover, strong adoption of the company’s telehealth solutions such as tele-ICU, tele-radiology and tele-pathology is a major positive.
Notably, the company’s Connected Care business revenues (24% of total revenues) soared 36% year over year to €1.56 billion, with a comparable sales growth of 42% in the third-quarter of 2020. Philips expects this strong momentum to continue in the fourth quarter of 2020. Moreover, the acquisition of BioTelemetry bodes well for the company’s Connected Care business.
Long-term earnings growth rate for Qorvo and Arrow Electronics is pegged at 15.8% and 9.8%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Philips (PHG) Expands Portfolio With BioTelemetry Acquisition
Koninklijke Philips N.V. (PHG - Free Report) recently inked an agreement to acquire BioTelemetry (BEAT - Free Report) , a provider of remote cardiac diagnostics and monitoring in the United States.
Per the deal, Philips will make a cash tender offer to buy all of BioTelemetry’s issued and outstanding shares for $72 per share. The implied enterprise value, including BioTelemetry’s cash and debt, is $2.8 billion.
Additionally, Philips will incorporate roughly 1,900 BioTelemetry employees in its Connected Care business segment. Further, the company expects to complete the acquisition in the first quarter of 2021.
Rationale Behind the Acquisition
The integration of BioTelemetry’s cardiac diagnostics and monitoring solutions with Philips’ existing portfolio, which includes real-time patient monitoring, therapeutic devices, telehealth and informatics, drives the expansion of the latter’s cardiac care portfolio.
Koninklijke Philips N.V. Price, Consensus and EPS Surprise
Koninklijke Philips N.V. price-consensus-eps-surprise-chart | Koninklijke Philips N.V. Quote
The acquisition enhances the company’s patient care management capabilities by improving patient care across care settings for multiple diseases and medical conditions at both hospitals and homes.
Philips provides services to approximately 300 million patients in hospitals and 10 million sleep and respiratory care patients per year in their homes. BioTelemetry monitors more than 1 million patients per year and above 30,000 unique referring physicians per month. Notably, the integration expands Philips’ customer base and will drive top-line growth in the long haul.
Further, the company expects the buyout to aid revenue growth and adjusted EBITA margin expansion in 2021. Moreover, the EBITA margin is expected to surpass 20% by 2025.
The growth will be majorly driven by cross-selling opportunities, geographical expansion, along with innovation in the company’s product line-up, such as Philips’ Health Suite digital platform.
Momentum in Connected Care Segment Aids Growth
Philips’ shares have gained 17% year to date compared with the Zacks Electronics - Miscellaneous Products industry’s growth of 16.4%.
Notably, Philips’ Connected Care segment benefits from the coronavirus-induced elevated demand in both Sleep & Respiratory Care and Monitoring & Analytics businesses.
Further, strong demand for patient monitors, hospital ventilators, computed tomography and portable ultrasound systems led by the pandemic is a key catalyst. Moreover, strong adoption of the company’s telehealth solutions such as tele-ICU, tele-radiology and tele-pathology is a major positive.
Notably, the company’s Connected Care business revenues (24% of total revenues) soared 36% year over year to €1.56 billion, with a comparable sales growth of 42% in the third-quarter of 2020. Philips expects this strong momentum to continue in the fourth quarter of 2020. Moreover, the acquisition of BioTelemetry bodes well for the company’s Connected Care business.
Zacks Rank & Stocks to Consider
Philips currently has a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader technology sector are Qorvo (QRVO - Free Report) and Arrow Electronics (ARW - Free Report) . Qorvo sports a Zacks Rank #1 (Strong Buy), while Arrow Electronics carries a Zacks Rank #2 (Buy), at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Long-term earnings growth rate for Qorvo and Arrow Electronics is pegged at 15.8% and 9.8%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>